GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Boundless Bio Inc (NAS:BOLD) » Definitions » Asset Impairment Charge

Boundless Bio (Boundless Bio) Asset Impairment Charge : $0.00 Mil (TTM As of Dec. 2023)


View and export this data going back to 2024. Start your Free Trial

What is Boundless Bio Asset Impairment Charge?

Boundless Bio's Asset Impairment Charge for the three months ended in Dec. 2023 was $0.00 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil.

Boundless Bio Asset Impairment Charge Historical Data

The historical data trend for Boundless Bio's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Boundless Bio Asset Impairment Charge Chart

Boundless Bio Annual Data
Trend Dec21 Dec22 Dec23
Asset Impairment Charge
- - -

Boundless Bio Quarterly Data
Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23
Asset Impairment Charge Get a 7-Day Free Trial - - - - -

Boundless Bio Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Boundless Bio Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of Boundless Bio's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.

Boundless Bio (Boundless Bio) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Boundless Bio Inc (NAS:BOLD) » Definitions » Asset Impairment Charge
Comparable Companies
Traded in Other Exchanges
N/A
Address
Website
https://www.boundlessbio.com
Boundless Bio Inc is a clinical-stage oncology company. It is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.

Boundless Bio (Boundless Bio) Headlines

From GuruFocus

Boundless Bio Announces Pricing of Initial Public Offering

By Business Wire • 03-27-2024